Newer developments in the treatment of Gram-positive infections

Bibliography

• Stemper ME, Shukla SK, Reed KD. Emergence and spread of community-associated methicillin-resistant Staphylococcus aureus in rural Wisconsin, 1989 to 1999. J Clin Microbiol 2004;42:5673-80
   PubMedGoogle Scholar
• Macgowan AP; BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. Antimicrob Chemother 2008;62(Suppl 2):105-14
   Google Scholar
• Grundmann H, Aires-de-Sousa M, Boyce J, Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006;368:874-85
   PubMed Web of Science ®Google Scholar
• Boyce JM. Methicillin-resistant Staphylococcus aureus in hospitals and long-term care facilities: microbiology, epidemiology, and preventive measures. Infect Control Hosp Epidemiol 1992;13:725-37
   PubMedGoogle Scholar
• National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85
   PubMed Web of Science ®Google Scholar
• Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases, 6th edition
   Google Scholar
• Appelbaum PC. MRSA – the tip of the iceberg. Clin Microbiol Infect 2006;12(Suppl 2):3-10
   PubMed Web of Science ®Google Scholar
• Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009;48:1596-600
   PubMed Web of Science ®Google Scholar
• Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006;42:224-33
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Reinert RR, Appelbaum PC, Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 2007;67:2355-82
   PubMed Web of Science ®Google Scholar
• Arthur M, Reynolds P, Courvalin P. Glycopeptide resistance in enterococci. Trends Microbiol 1996;4:401-7
   PubMed Web of Science ®Google Scholar
• Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 2003;26:876-9
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Lomaestro BM, Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Gold HS, Cohen RA, Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006;57:699-704
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98
   PubMedGoogle Scholar
• De Górgolas M, Avilés P, Verdejo C, Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 1995;39:953-7
   PubMed Web of Science ®Google Scholar
• Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-8
   PubMed Web of Science ®Google Scholar
• Masters PA, O’Bryan TA, Zurlo J, Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003;163:402-10
   PubMed Web of Science ®Google Scholar
• Clumeck N, Marcelis L, Amiri-Lamraski MH, Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother 1984;13(Suppl C):17-22
   PubMedGoogle Scholar
• Ruhe JJ, Monson T, Bradsher RW, Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005;40:1429-34
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens – a global perspective. Semin Respir Infect 2000;15:195-207
   PubMedGoogle Scholar
• Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-41
   PubMed Web of Science ®Google Scholar
• Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 1998;18:345-57
   PubMedGoogle Scholar
• Gagnon RF, Richards GK, Wiesenfeld L. Staphylococcus epidermidis biofilms: unexpected outcome of double and triple antibiotic combinations with rifampin. ASAIO Trans 1991;37:M158-60
   PubMedGoogle Scholar
• Nimmo GR, Bell JM, Mitchell D, Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989 – 1999. Microb Drug Resist 2003;9:155-60
   PubMed Web of Science ®Google Scholar
• Hansson S, Singh R, Gudkov AT, Structural insights into fusidic acid resistance and sensitivity in EF-G. J Mol Biol 2005;348:939-49
   PubMedGoogle Scholar
• Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999;12(Suppl 2):S35-44
   PubMed Web of Science ®Google Scholar
• Besier S, Ludwig A, Brade V, Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol Microbiol 2003;47:463-9
   PubMedGoogle Scholar
• Whitby M. Fusidic acid in septicaemia and endocarditis. Int J Antimicrob Agents 1999;12(Suppl 2):S17-22
   PubMedGoogle Scholar
• Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999;12(Suppl 2):S59-66
   PubMed Web of Science ®Google Scholar
• Whitby M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1999;12(Suppl 2):S67-71
   PubMed Web of Science ®Google Scholar
• Christiansen K. Fusidic acid adverse drug reactions. Int J Antimicrob Agents 1999;12(Suppl 2):S3-9
   PubMed Web of Science ®Google Scholar
• Meka VG, Pillai SK, Sakoulas G. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004;190:311-17
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42:1129-40
   PubMed Web of Science ®Google Scholar
• Jones RN, Fritsche TR, Sader HS, Zyvox annual appraisal of potency and spectrum program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 2007;59:199-209
   PubMed Web of Science ®Google Scholar
• Kuti JL, Kiffer CR, Mendes CM, Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 2008;14:116-23
   PubMed Web of Science ®Google Scholar
• Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 2006;26:1784-93
   PubMed Web of Science ®Google Scholar
• Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome [review]. Pharmacotherapy 2007;27:1189-97
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Tack KJ, Bouza E, Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009;48:203-12
   PubMed Web of Science ®Google Scholar
• Grau S, Rubio-Terrés C. Pharmacoeconomics of linezolid. Expert Opin Pharmacother 2008;9:987-1000
   PubMed Web of Science ®Google Scholar
• Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008;6:637-55
   PubMed Web of Science ®Google Scholar
• Synercid: Drug Informations. Data available from: http://www.drugs.com/pro/synercid.html [Last accessed 28 July 2009]
   Google Scholar
• Chambers HF. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin resistant Staphylococcus aureus. J Antimicrob Chemother 1992;30:117-22
   PubMedGoogle Scholar
• Péchère JC. Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin. Antimicrob Chemother 1999;44(Suppl A):11-8
   Google Scholar
• Nichols RL, Graham DR, Barriere SL, Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999;44:263-73
   PubMed Web of Science ®Google Scholar
• Fagon J, Patrick H, Haas DW, Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161:753-62
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003;36:473-81
   PubMed Web of Science ®Google Scholar
• Baysallar M, Kilic A, Aydogan H, Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey. Int J Antimicrob Agents 2004;23:510-12
   PubMedGoogle Scholar
• Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56:611-14
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Kelesidis T, Kelesidis I, Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008;62:45-55
   PubMed Web of Science ®Google Scholar
• Tiengrim S, Tribuddharat C, Thamlikitkul V. In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand. J Med Assoc Thai 2006;89(Suppl 5):S102-5
   PubMedGoogle Scholar
• Trakulsomboon S, Thamlikitkul V. In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus isolated from the patients at Siriraj Hospital. J Infect Dis Antimicrob Agents 2006;23:1-4
   Google Scholar
• MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update [review]. J Antimicrob Chemother 2008;62(Suppl 1):11-6
   PubMed Web of Science ®Google Scholar
• Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009;53:2756-61
   PubMed Web of Science ®Google Scholar
• Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob Agents Chemother 2009;53:1165-9
   PubMed Web of Science ®Google Scholar
• Sacchidanand S, Penn RL, Embil JM, Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with cSSSIs: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005;9:251-61
   PubMed Web of Science ®Google Scholar
• Florescu I, Beuran M, Dimov R, Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008;62(Suppl 1):17-28
   PubMed Web of Science ®Google Scholar
• Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006;43(4):518-24
   PubMedGoogle Scholar
• Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:2538-44
   PubMed Web of Science ®Google Scholar
• Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1919-22
   PubMed Web of Science ®Google Scholar
• Enoch DA, Bygott JM, Daly ML, Daptomycin. J Infect 2007;55:205-13
   PubMed Web of Science ®Google Scholar
• Dvorchik B. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol 2004;44:715-22
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, Vanpraagh AD, Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52
   PubMed Web of Science ®Google Scholar
• Lee SY, Fan HW, Kuti JL, Update on daptomycin: the first approved lipopeptide antibiotic [review]. Expert Opin Pharmacother 2006;7:1381-97
   PubMedGoogle Scholar
• Martone WJ, Lamp KC. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr Med Res Opin 2006;22:2337-43
   PubMed Web of Science ®Google Scholar
• Davis SL, McKinnon PS, Hall LM, Daptomycin versus vancomycin for cSSSIs: clinical and economic outcomes. Pharmacotherapy 2007;27:1611-18
   PubMed Web of Science ®Google Scholar
• Kim A, Suecof LA, Sutherland CA, In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 2008;52:3941-6
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr, Boucher HW, Corey GR, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65
   PubMed Web of Science ®Google Scholar
• Pace JL, Judice JK. Telavancin (Theravance). Curr Opin Investig Drugs 2005;6:216-25
   PubMedGoogle Scholar
• Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram-positive infections [review]. Expert Opin Investig Drugs 2007;16:347-57
   PubMed Web of Science ®Google Scholar
• Higgins DL, Chang R, Debabov DV, Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1127-34
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Wiens T, Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004;48:3043-50
   PubMed Web of Science ®Google Scholar
• Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:3163-5
   PubMed Web of Science ®Google Scholar
• Stucki A, Gerber P, Acosta F, Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 2006;50:770-3
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, O’Riordan WD, Lau WK, Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-7
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Chu VH, O’Riordan WD, Telavancin versus standard therapy for treatment of cSSSIs caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-7
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Tang DM, Manausa RM. A review of telavancin in the treatment of cSSSIs. Ther Clin Risk Manag 2008;4:235-44
   PubMedGoogle Scholar
• Attwood RJ, LaPlante KL. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 2007;64:2335-48
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Sun HK, Seltzer E, Pharmacokinetics of dalbavancin in plasma and skin blister. J Antimicrob Chemother 2007;60:681-4
   PubMed Web of Science ®Google Scholar
• Dowell JA, Goldstein BP, Buckwalter M, Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. Clin Pharmacol 2008;48:1063-8
   Google Scholar
• Seltzer E, Dorr MB, Goldstein BP, Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003;37:1298-303
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J, Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40:374-80
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of cSSSIs. Clin Infect Dis 2005;41:1407-15
   PubMed Web of Science ®Google Scholar
• Billeter M, Zervos MJ, Chen AY, Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008;46:577-83
   PubMed Web of Science ®Google Scholar
• Kim SJ, Cegelski L, Stueber D, Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 2008;377:281-93
   PubMed Web of Science ®Google Scholar
• Crandon J, Nicolau DP. Oritavancin: a potential weapon in the battle against serious gram-positive pathogens. Future Microbiol 2008;3:251-63
   PubMedGoogle Scholar
• Bhavnani SM, Passarell JA, Owen JS, Pharmacokinetic–pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006;50:994-1000
   PubMed Web of Science ®Google Scholar
• Poulakou G, Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to gram-positive pathogens. Expert Opinion Investig Drugs 2008;17:225-43
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Schleimer M, Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004;48:2570-5
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr, Pypstra R, Kahn JB, Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007;51:2378-87
   PubMed Web of Science ®Google Scholar
• Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob Agents Chemother 2008;52:2389-94
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother 2008;52:3492-6
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55
   PubMed Web of Science ®Google Scholar
• Phase III top-line study results in community-acquired pneumonia (CAP) patients requiring hospitalization met the primary endpoint of non-inferiority versus the study comparators. Basel, Switzerland: Basilea Pharmaceutica Ltd (SWX:BSLN). 14 Sept 2007. Available from: http://www.basilea.com/template_loader.php?tplpage_id=34&mode=details&id=131. [Last accessed 10 February 2009]
   Google Scholar
• Basilea announced today that the ceftobiprole phase III top-line study results in hospital-acquired pneumonia (HAP) met the primary endpoint of non-inferiority versus combination therapy of ceftazidime plus linezolid. Basel, Switzerland: Basilea Pharmaceutica Ltd (SWX:BSLN). 9 Oct. 2007 Available from: http://www.basilea.com/template_loader.php?tplpage_id=34&mode=details&id=144 [Last accessed 10 February 2009]
   Google Scholar
• Mushtaq S, Warner M, Ge Y, In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60:300-11
   PubMed Web of Science ®Google Scholar
• Sader HS, Fritsche TR, Kaniga K, Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49:3501-12
   PubMed Web of Science ®Google Scholar
• Kontou P, Kuti JL, Nicolau DP. Ceftobiprole: the first anti-MRSA cephalosporin antibiotic. Formulary 2008;43:66-78
   Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007;51:3397-400
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, Phase 2 study of ceftaroline versus standard therapy in treatment of cSSSIs. Antimicrob Agents Chemother 2007;51:3612-16
   PubMed Web of Science ®Google Scholar
• Sincak CA, Schmidt JM. Iclaprim, a novel diamidinopyrimidine for the treatment of resistant gram-positive infection. Ann Pharmacother 2009;43:1107-14
   PubMed Web of Science ®Google Scholar
• Brandt R, Warrington S, McBurney A, Tolerability and pharmacokinetics of single and repeat ascending doses of iclaprim in healthy adults (A-804). In: Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA; Sep 17-20, 2007
   Google Scholar
• Stevens D, Leighton A, Dankner W, Efficacy of iclaprim in complicated skin and skin structure infections: preliminary results of ASSIST-1 (1079). In: Abstracts of the 45th Annual Meeting of Infectious Diseases Society of America, San Diego, CA; Sep 21-24, 2005
   Google Scholar
• Leighton A, Dankner W, Stevens D, Safety of iclaprim in complicated skin and skin structure infections: ASSIST-1 results (1104). In: Abstracts of the 45th Annual Meeting of Infectious Disease Society of America, San Diego, CA; Sep 21-24, 2005
   Google Scholar
• FDA issues Complete Response Letter for Iclaprim. Data available from: http://www.medicalnewstoday.com/articles/135981.php [Last accessed 16 September 2009]
   Google Scholar
• Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009. [Epub ahead of print]
   PubMedGoogle Scholar
• Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007 – 2008). Diagn Microbiol Infect Dis 2009;65:158-62
   PubMed Web of Science ®Google Scholar
• Krause KM, Renelli M, Difuntorum S, In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008;52:2647-52
   PubMed Web of Science ®Google Scholar
• Arhin FF, Draghi DC, Pillar CM, Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother 2009. [Epub ahead of print]
   Google Scholar
• Jones ME. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007;13(Suppl 2):17-24
   PubMedGoogle Scholar